Patents for A61P 35 - Antineoplastic agents (221,099)
05/2005
05/25/2005EP1531842A2 Regulation of cell growth by muc1
05/25/2005EP1531830A1 Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations
05/25/2005EP1531824A2 Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders
05/25/2005EP1531817A1 Glycinamide derivatives as raf-kinase inhibitors
05/25/2005EP1531812A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis
05/25/2005EP1531808A1 Peroxynitrite rearrangement catalysts used for the treatment or prophylaxis of diseases caused by peroxynitrite-mediated reactions
05/25/2005EP1531806A2 Use of thio-oxindole derivatives in treatment of hormone-related conditions
05/25/2005EP1531804A1 Method of inhibiting angiogenesis
05/25/2005EP1531803A1 Method of inhibiting prostate cancer cell proliferation
05/25/2005EP1531800A2 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
05/25/2005EP1531716A2 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs
05/25/2005EP1438390A4 Circadian control of stem/progenitor cell self-renewal and differentiation and of clock controlled gene expression
05/25/2005EP1372670B1 Caloporoside derivatives, methods for the production thereof and their use
05/25/2005EP1365762A4 Method for increasing leptin levels using nicotinic acid compounds
05/25/2005EP1341791B1 Thioether substituted imidazoquinolines
05/25/2005EP1322286B1 Polymeric delivery formulations of leuprolide with improved efficacy
05/25/2005EP1307594A4 Association of sim2 with cancer
05/25/2005EP1287137B1 REGULATION OF HUMAN $g(a)1A?ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR
05/25/2005EP1286673B1 Ligands of integrin receptors
05/25/2005EP1279039A4 Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
05/25/2005EP1165615B1 MONOCLONAL ANTIBODIES AGAINST HUMAN PROTEIN Mcm3, PROCESS FOR THEIR PRODUCTION, AND THEIR USE
05/25/2005EP1165106B1 Composition and method for inducing apoptosis in prostate cancer cells by m-dna and mcc
05/25/2005EP1163335B1 MATERIALS AND METHODS RELATING TO MODULATION OF p66 EXPRESSION
05/25/2005EP0994903B1 Methods and compositions for galactosylated glycoproteins
05/25/2005EP0966304B1 Site-specific drug delivery
05/25/2005EP0907370B1 Hla-a2.1 binding peptides and their uses
05/25/2005EP0904274B1 Farnesyl transferase inhibitors
05/25/2005EP0871702B1 Cytokine designated lerk-7
05/25/2005EP0813419B1 Modulators of regulatory proteins
05/25/2005EP0688227B1 Production of human papillomavirus capsid protein and virus-like particles
05/25/2005CN1620510A Cytokine protein family
05/25/2005CN1620500A Corona-virus-like particles comprising functionally deleted genomes
05/25/2005CN1620468A Novel anti-igf-ir antibodies and uses thereof
05/25/2005CN1620467A Secreted protein
05/25/2005CN1620466A Cystine-knot fold protein
05/25/2005CN1620464A Peptides for the treatment of cancer associated with the human papilloma virus (hpv) and other epithelial tumors
05/25/2005CN1620458A 噻吩并嘧啶 Thienopyrimidine
05/25/2005CN1620457A Tetracyclic heterocompounds as estrogen receptor modulators
05/25/2005CN1620452A 3, 4-dihydro-1h-isoquinoloin-2-yl-derivatives
05/25/2005CN1620451A Benzhydryl derivatives
05/25/2005CN1620448A Piperidine-2, 6-diones heterocyclically substituted in the 3-position
05/25/2005CN1620434A Pyrrolidine-2-ones as factor Xa inhibitors
05/25/2005CN1620433A Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme
05/25/2005CN1620431A (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
05/25/2005CN1620424A Compounds for the treatment of inflammatory disorders
05/25/2005CN1620414A 维生素d类似物 Vitamin d analogues
05/25/2005CN1620314A Gas micro-liposome compound
05/25/2005CN1620313A Method of examining effect of angiogenesis inhibitors mediated by the inhibition of integrin expression
05/25/2005CN1620311A Therapeutic agent
05/25/2005CN1620309A Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
05/25/2005CN1620305A Method of inducing apoptosis and compositions therefor
05/25/2005CN1620299A Alpha-hydroxy-2-methylene-10-nor-pregnacalciferol and its uses
05/25/2005CN1620296A Substituted quinazoline derivatives as inhibitors of aurora kinases
05/25/2005CN1620294A Pyrimidine A2b selective antagonist compounds, their synthesis and use
05/25/2005CN1620291A 3-(imidazolyl)-2-alkoxypropanoic acids as TAFIA inhibitors
05/25/2005CN1620289A Novel metalloporphyrins and their uses as radiosensitizers for radiation therapy
05/25/2005CN1620285A Novel microsphere and method for production thereof
05/25/2005CN1620283A Dispersions for formulating slightly or poorly soluble active ingredients
05/25/2005CN1618978A Configuration of cell facter IL-24 eucargon expression carrier and application
05/25/2005CN1618969A Mammalian sytokine-like polypeptide-10
05/25/2005CN1618946A Cancer prevention health protection fermented wine
05/25/2005CN1618810A New mastocancer related protein and its specificity multiclone antibody
05/25/2005CN1618809A New mastocancer related protein and its specificity multiclone antibody
05/25/2005CN1618803A Recombinated phycobiliprotein and its preparation method and application
05/25/2005CN1618465A 联合疫苗组合物 Combined vaccine composition
05/25/2005CN1618459A Translation initiation factor eIF-5A and medical application of it and syntenin complex
05/25/2005CN1618447A Traditional Chinese medicine prescription for treating tumour, prepn. process use thereof
05/25/2005CN1618425A Composition contg. theaflavin and its derivatives, prepn. method and application thereof
05/25/2005CN1203090C Cyclic bonding inhibitor
05/25/2005CN1203074C Pentacycle taxane compounds
05/25/2005CN1203071C Polysaccharidic esters of N-derivatives of glutamic acid
05/25/2005CN1203070C Thrombin receptor antagonists
05/25/2005CN1203058C Piperidine derivatives and drugs containing these derivatives as active ingredient
05/25/2005CN1203055C Method and composition for treating or preventing bacterial infection
05/25/2005CN1202836C Toad skin preparation and productive process thereof
05/25/2005CN1202828C Use of diphosphonic acid in preparing medicine for treatment of vasculogenesis
05/25/2005CN1202817C Solid disperser of quick-releasing vitamine A acid
05/25/2005CA2448831A1 Multi-stage cascade boosting vaccine
05/24/2005US6897319 Therapeutic drugs for treating central nervous system disorders
05/24/2005US6897318 Process for making substituted pyrazoles
05/24/2005US6897316 Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents
05/24/2005US6897294 Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
05/24/2005US6897235 Compositions useful for the treatment of pathologies responding to the activation of PPAR-γ receptor
05/24/2005US6897231 Jun n- terminal kinase inhibitors such as 3-(4-methoxyphenyl)-1H-indazole
05/24/2005US6897223 Nitrogen compounds such as Benzyl-8-methyl-5,7-dioxo-1,5,6,7-tetrahydro-(1,2,4)triazolo(1,5-a)pyridine -2-carboxylic acid benzylamide, used for prophylaxis of arthritis, inflammation or cancer
05/24/2005US6897221 Urea substituted imidazoquinolines
05/24/2005US6897220 Antiproliferative agents
05/24/2005US6897218 Nitric oxide donors based on metallic centers
05/24/2005US6897214 Quinazoline derivatives
05/24/2005US6897211 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors
05/24/2005US6897210 Anticancer agents; antiarthritic agents
05/24/2005US6897209 Thrombosis; anticholesterol agents; cardiovascular disorders; antiinflammatory agents; anticancer agents
05/24/2005US6897207 Kinase inhibitors; angiogenesis inhibitors, anticancer agents, antiinflammatory agents and chronic obstructive pulmonary disease inhibitors
05/24/2005US6897203 Polysaccharidic esters of retinoic acid
05/24/2005US6897054 For controlling in vitro cell proliferation; genetic engineering
05/24/2005US6897050 Desaturase genes and their use
05/24/2005US6897044 Drugs for treatment of cancer/autoimmune disorders; apoptosis promoters
05/24/2005US6897034 Antitumor agents; drug immobilized to oligopeptide; complexing; testing, calibration of complex to see if capable of being split enzyme; drug design
05/24/2005US6896907 Use of bioactive fraction from cow urine distillate (‘go-mutra’) as a bio-enhancer of anti-infective, anti-cancer agents and nutrients
05/24/2005US6896885 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma